Copyright © 2000 by the European Society of Cardiology.
Profile of plasma N-terminal proBNP following acute myocardial infarction. Correlation with left ventricular systolic dysfunction
Department of Medicine and Therapeutics, University of Leicester, Leicester, U.K.
revised November 29, 1999; accepted December 1, 1999
Abstract
Aims The aims of this study were to describe the temporal pattern of plasma N-terminal pro-brain natriuretic peptide, to examine the optimum time of sampling and to compare plasma N-terminal pro-brain natriuretic peptide to clinical criteria in terms of identification of impaired left ventricular systolic function following acute myocardial infarction.
Methods and Results Measurements of N-terminal pro-brain natriuretic peptide were made in 60 patients at 1448h, 4972h, 73120h, 121192h following myocardial infarction and at 6 weeks in survivors. Left ventricular wall motion index was assessed during hospitalization (WMI-1) and at 6 weeks (WMI-2). N-terminal pro-brain natriuretic peptide levels were elevated at all time points, to a greater extent in anterior compared to inferior infarction (P<0·05). A biphasic profile of plasma concentration was observed in anterior infarction with peaks at 1448h and 121192h. This was sustained at 6 weeks. N-terminal pro- brain natriuretic peptide at 73120h was the best independent predictor of WMI-1 (P<0·005). N-terminal pro-brain natriuretic peptide was higher at all times in patients who received ACE inhibitor therapy compared to those who did not (P<0·005). N-terminal pro-brain natriuretic peptide at 73120h (R2=17·7%, P=0·005) and previous myocardial infarction (R2=5·3%, P<0·05) were independent predictors of poor outcome (WMI-2
1·2 or death by 6 weeks).
Conclusions A biphasic pattern of plasma N-terminal pro-brain natriuretic peptide is seen after anterior myocardial infarction. Plasma level is strongly correlated to wall motion index soon after and remote from acute myocardial infarction. Plasma N-terminal pro-brain natriuretic peptide measured later in hospitalization better predicts poor outcome following myocardial infarction than when it is measured in the immediate post infarction period.
Key Words: Brain natriuretic peptide, neurohormones, acute myocardial infarction, left ventricular systolic dysfunction
f1 Correspondence: Dr L. L. Ng, Department of Medicine & Therapeutics, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, U.K.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. R. Sinnaeve, J. A. Ezekowitz, K. Bogaerts, W. Droogne, R. Jarai, K. Huber, C. B. Granger, W. J. Desmet, P. W. Armstrong, F. J. Van de Werf, et al. Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis Eur. Heart J., September 2, 2009; 30(18): 2213 - 2219. [Abstract] [Full Text] [PDF] |
||||
![]() |
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Circulation, April 3, 2007; 115(13): e356 - e375. [Full Text] [PDF] |
||||
![]() |
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF] |
||||
![]() |
G. Kwan, S. R. Isakson, J. Beede, P. Clopton, A. S. Maisel, and R. L. Fitzgerald Short-Term Serial Sampling of Natriuretic Peptides in Patients Presenting With Chest Pain J. Am. Coll. Cardiol., March 20, 2007; 49(11): 1186 - 1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kelly, G. Cockerill, L. L. Ng, M. Thompson, S. Khan, N. J. Samani, and I. B. Squire Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study Eur. Heart J., March 5, 2007; (2007) ehm003v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ben-Dor, M. Haim, E. Rechavia, D. Murninkas, D. Harell, A. Porter, Z. Iakobishvili, A. Battler, and D. Hasdai Serum NT-proBNP Concentrations in the Early Phase Do Not Predict the Severity of Systolic or Diastolic Left Ventricular Dysfunction Among Patients With ST-Elevation Acute Myocardial Infarction Angiology, January 1, 2007; 57(6): 686 - 693. [Abstract] [PDF] |
||||
![]() |
P.A. Gould, J. D'Agostino, H.G. Schneider, and D.M. Kaye Influence of atrial fibrillation on cardiac brain natriuretic peptide release during haemodynamic stress in heart failure Eur J Heart Fail, May 1, 2006; 8(3): 263 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Morrow, J. A. de Lemos, M. A. Blazing, M. S. Sabatine, S. A. Murphy, P. Jarolim, H. D. White, K. A. A. Fox, R. M. Califf, E. Braunwald, et al. Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients With Unstable Coronary Artery Disease JAMA, December 14, 2005; 294(22): 2866 - 2871. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Reyes, G. Fores, R. Hugo Rodriguez-Abella, G. Cuerpo, J. L. Vallejo, C. Romero, and A. Pinto NT-proBNP in cardiac surgery: a new tool for the management of our patients? Interactive CardioVascular and Thoracic Surgery, June 1, 2005; 4(3): 242 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kragelund, B. Gronning, L. Kober, P. Hildebrandt, and R. Steffensen N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease N. Engl. J. Med., February 17, 2005; 352(7): 666 - 675. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lindahl, J. Lindback, T. Jernberg, N. Johnston, M. Stridsberg, P. Venge, and L. Wallentin Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: A Fragmin and fast Revascularisation during InStability in coronary artery disease (FRISC)-II substudy J. Am. Coll. Cardiol., February 15, 2005; 45(4): 533 - 541. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Williams, L. L. Ng, R. J. O'Brien, S. Taylor, D. J. Wright, and L.-B. Tan Is plasma N-BNP a good indicator of the functional reserve of failing hearts? The FRESH-BNP study Eur J Heart Fail, December 1, 2004; 6(7): 891 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Jernberg, B. Lindahl, A. Siegbahn, B. Andren, G. Frostfeldt, B. Lagerqvist, M. Stridsberg, P. Venge, and L. Wallentin Reply J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1933 - 1933. [Full Text] [PDF] |
||||
![]() |
P R Kalra, A Gomma, C Daly, J R Clague, I B Squire, L L Ng, and K F Fox Reduction in plasma concentrations of N terminal pro B type natriuretic peptide following percutaneous coronary intervention Heart, November 1, 2004; 90(11): 1334 - 1335. [Full Text] [PDF] |
||||
![]() |
R. Latini, A. P. Maggioni, G. Peri, L. Gonzini, D. Lucci, P. Mocarelli, L. Vago, F. Pasqualini, S. Signorini, D. Soldateschi, et al. Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial Infarction Circulation, October 19, 2004; 110(16): 2349 - 2354. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-R. Blom, A. W.J. van 't Hof, J. P.S. Henriques, J. H. Geertman, R. Slingerland, and J. C.A. Hoorntje NT-proBNP: a marker for successful myocardial reperfusion in AMI patients treated with primary percutaneous coronary intervention Eur J Heart Fail, October 1, 2004; 6(6): 749 - 752. [Full Text] [PDF] |
||||
![]() |
F. Hartmann, M. Packer, A. J.S. Coats, M. B. Fowler, H. Krum, P. Mohacsi, J. L. Rouleau, M. Tendera, A. Castaigne, S. D. Anker, et al. Prognostic Impact of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial Circulation, September 28, 2004; 110(13): 1780 - 1786. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ala-Kopsala, J. Magga, K. Peuhkurinen, J. Leipala, H. Ruskoaho, J. Leppaluoto, and O. Vuolteenaho Molecular Heterogeneity Has a Major Impact on the Measurement of Circulating N-Terminal Fragments of A- and B-Type Natriuretic Peptides Clin. Chem., September 1, 2004; 50(9): 1576 - 1588. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cochet, M. Zeller, Y. Cottin, C. Robert-Valla, A. Lalande, I. L'Huilllier, A. Comte, P. M. Walker, J. Desgres, J.-E. Wolf, et al. The extent of myocardial damage assessed by contrast-enhanced MRI is a major determinant of N-BNP concentration after myocardial infarction Eur J Heart Fail, August 1, 2004; 6(5): 555 - 560. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Mega, D. A. Morrow, J. A. de Lemos, M. S. Sabatine, S. A. Murphy, N. Rifai, C. M. Gibson, E. M. Antman, and E. Braunwald B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: An ENTIRE-TIMI-23 substudy J. Am. Coll. Cardiol., July 21, 2004; 44(2): 335 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Galvani, F. Ottani, L. Oltrona, D. Ardissino, G. F. Gensini, A. P. Maggioni, P. M. Mannucci, N. Mininni, M. D. Prando, M. Tubaro, et al. N-Terminal Pro-Brain Natriuretic Peptide on Admission Has Prognostic Value Across the Whole Spectrum of Acute Coronary Syndromes Circulation, July 13, 2004; 110(2): 128 - 134. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.A. McDonagh, S. Holmer, I. Raymond, A. Luchner, P. Hildebrant, and H.J. Dargie NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies Eur J Heart Fail, March 15, 2004; 6(3): 269 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bayes-Genis, M. Santalo-Bel, E. Zapico-Muniz, L. Lopez, C. Cotes, J. Bellido, R. Leta, P. Casan, and J. Ordonez-Llanos N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction Eur J Heart Fail, March 15, 2004; 6(3): 301 - 308. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Galvani, D. Ferrini, and F. Ottani Natriuretic peptides for risk stratification of patients with acute coronary syndromes Eur J Heart Fail, March 15, 2004; 6(3): 327 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Hartmann, M. Packer, A. J.S. Coats, M. B. Fowler, H. Krum, P. Mohacsi, J. L. Rouleau, M. Tendera, A. Castaigne, J. Trawinski, et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy Eur J Heart Fail, March 15, 2004; 6(3): 343 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Tapanainen, K. S. Lindgren, T. H. Makikallio, O. Vuolteenaho, J. Leppaluoto, and H. V. Huikuri Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era J. Am. Coll. Cardiol., March 3, 2004; 43(5): 757 - 763. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Berendes, C. Schmidt, H. Van Aken, M. G. Hartlage, M. Rothenburger, S. Wirtz, H. H. Scheld, G. Brodner, and M. Walter A-Type and B-Type Natriuretic Peptides in Cardiac Surgical Procedures Anesth. Analg., January 1, 2004; 98(1): 11 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. O'Brien, I. B. Squire, B. Demme, J. E. Davies, and L. L. Ng Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF Eur J Heart Fail, August 1, 2003; 5(4): 499 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Omland, A. Persson, L. Ng, R. O'Brien, T. Karlsson, J. Herlitz, M. Hartford, and K. Caidahl N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes Circulation, December 3, 2002; 106(23): 2913 - 2918. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kruger, J.u. Graf, D. Kunz, T. Stickel, P. Hanrath, and U. Janssens brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure J. Am. Coll. Cardiol., August 21, 2002; 40(4): 718 - 722. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Luchner, C. Hengstenberg, H. Lowel, J. Trawinski, M. Baumann, G. A.J. Riegger, H. Schunkert, and S. Holmer N-Terminal Pro-Brain Natriuretic Peptide After Myocardial Infarction: A Marker Of Cardio-Renal Function Hypertension, January 1, 2002; 39(1): 99 - 104. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. de Lemos, D. A. Morrow, J. H. Bentley, T. Omland, M. S. Sabatine, C. H. McCabe, C. Hall, C. P. Cannon, and E. Braunwald The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes N. Engl. J. Med., October 4, 2001; 345(14): 1014 - 1021. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.D. Struthers N-terminal proBNP--the most cost effective way to identify post myocardial infarction left ventriular dysfunction? Eur. Heart J., September 2, 2000; 21(18): 1490 - 1492. [PDF] |
||||











